With a possible fix for compliance and side-effect issues in Alzheimer's disease (AD), Corium International Inc. drew attention from Wall Street by way of positive top-line phase I data that disclosed pharmacokinetics (PK) of its Corplex once-weekly transdermal patch delivering the acetylcholinesterase inhibitor donepezil, sold as oral, daily Aricept by Pfizer Inc.